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Abstract
Background The degree of inflammatory response with
cytokine release is associated with poor outcomes after
aneurysmal subarachnoid hemorrhage (SAH). Previously,
we reported on an association between systemic IL-6 levels
and clinical outcome in patients with aneurysmal SAH. The
intention was to assess the impact of nonsteroidal anti-
inflammatory drugs (NSAIDs) and acetaminophen on the
inflammatory response after SAH.
Methods Our method involved exploratory analysis of
data and samples collected within a previous study. In 138
patients with SAH, systemic interleukin (IL-6) and
c-reactive protein (CRP) were measured daily up to day 14
after SAH. The correlations among the cumulatively
applied amount of NSAIDs, inflammatory parameters, and
clinical outcome were calculated.
Results An inverse correlation between cumulatively
applied NSAIDs and both IL-6 and CRP levels was found
(r = -0.437, p < 0.001 and r = -0.369, p < 0.001
respectively). Multivariable linear regression analysis
showed a cumulative amount of NSAIDs to be independently
predictive for systemic IL-6 and CRP levels. The cumulative
amount of NSAIDs reduced the odds for unfavorable out-
come, defined as Glasgow outcome scale 1–3.
Conclusions The results indicate a potential beneficial
effect of NSAIDs in patients with SAH in terms of
ameliorating inflammatory response, which might have an
impact on outcome.
Keywords Nonsteroidal anti-inflammatory drugs 
Inflammation  Subarachnoid hemorrhage  Interleukin-6
Introduction
Considerable advances in diagnosis, surgical treatment,
and neurocritical care medicine have reduced the risk of
mortality after aneurysmal subarachnoid hemorrhage
(SAH). However, the functional outcome remains poor in
these patients [1]. Ample evidence derived from experi-
mental settings suggests that inflammatory pathways with
cytokine release, such as interleukin-6 (IL-6), are involved
in the pathogenesis of cerebral injury [2–4]. Recently, we
reported on a positive correlation between systemic IL-6
levels and poor outcomes in patients with SAH [5]. Several
drugs, including nonsteroidal anti-inflammatory drugs
(NSAIDs), aimed at limiting the inflammatory response,
have been experimentally validated, with varying levels of
success [2, 6–11]. However, clinical studies specifically
examining the effect of NSAIDs on inflammatory response
and outcome after SAH are virtually nonexistent. The
present study intended to elucidate the potential impact of
NSAID application—including acetaminophen—on
inflammatory parameters, in particular IL-6 levels, in the
acute phase after SAH [5].
Materials and Methods
The current study is an exploratory analysis of data and
samples collected within a previous study [5]. In brief, the
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prospective observational study was carried out at a single
academic tertiary care center during a 3-year period.
Because of its purely exploratory design, a sample size
calculation was not determined. The study was approved
by the local ethics committee. All patients with confirmed
aneurysmal SAH were included. The diagnosis was based
on CT and angiography studies. Exclusion criteria included
admission >3 days after ictus, uncertain time of ictus,
death within 3 days after admission, and conservative or
delayed aneurysm treatment. The severity at time of
admission was assessed based on the World Federation of
Neurological Surgeons (WFNS) grading. All patients were
treated according to a standardized treatment protocol as
previously described [5, 12–14]. In all patients, mean
arterial blood pressure (MAP) was monitored by an arterial
catheter. MAP was held constant within the range of
80–120 mmHg after aneurysm securement. Blood glucose
concentration was measured at least q 4 h and was held
constant within the range of 5–8 mmol/ml. In intubated and
ventilated patients, arterial pO2 and pCO2 were measured
at least q 4 h and kept within the following range: paO2:
>12.0 kPa; and pCO2: 4.8–5.6 kPa. The duration of
sedation was kept as short as possible. Indications for long-
term sedation are intracranial hypertension and/or severe
cardiac or respiratory failure. Core body temperature
C38 C was regarded as fever and was treated accordingly.
NSAID prescription in general was at the discretion of the
attending neurointensivist on duty, based on a stepwise
management scheme starting with acetaminophen (INN,
paracetamol) followed by dipyrone (INN, metamizol),
diclofenac, and ibuprofen. Contraindication for acetami-
nophen was pathologically high lever enzymes. Known
ulcer diseases, erosive gastritis or colitis, coagulation dis-
orders, and unsecured aneurysms were contraindications
for ibuprofen and diclofenac. Dosages were adapted to
body weight and kidney function. Maximum dosages per
day were 4 g for acetaminophen, 4 g for dipyrone, 150 mg
for diclofenac, and 2.4 g for ibuprofen. As for the inflam-
matory parameter, daily systemic c-reactive protein (CRP)
and IL-6 levels were measured in terms of clinical routine
from day 3 to 14 after SAH. Physiological IL-6 and CRP
levels were <3.3 ng/l and <5 mg/l, respectively. Blood
sampling was performed early in the morning between
06:30 and 07:30 h. The samples underwent no freeze–thaw
cycle as the samples were analyzed once immediately by
the Institute of Clinical Chemistry, University Hospital
Zurich. IL-6 and CRP levels were not an integral part of the
NSAID management scheme. The principal investigator
(C.M.) was not a treating physician and did not have any
influence on NSAID prescription.
Infectious complications were assessed as confounding
factors, as they influence the level of inflammatory
parameters [15]. Criteria for the presence of an infectious
complication are summarized in Table 1. Having a poten-
tial impact on inflammatory serum parameters as well as on
prescription of NSAIDs, the application of mild therapeutic
hypothermia (intravascular catheter-based heat exchange
system, Zoll Medical, Chelmsford, MA, USA; target brain
temperature 33–34 C) was also included in the analysis.
Indications for hypothermia included elevated intracranial
pressure and/or symptomatic CVS refractory to conven-
tional treatment [16]. Having a direct impact on outcome,
the occurrence of cerebral infarction was assessed as a
confounding factor [17]. Cerebral infarction was defined as
new ischemic lesions, which could not be attributed to
surgery or endovascular intervention. All patients had a
baseline cranial computed tomography. Further scans were
obtained within 24 h after the aneurysm-securing proce-
dure, at discharge, and if the patient had neurological
worsening. The clinical outcome was assessed 3 months
after SAH in the outpatient clinic, based on the Glasgow
outcome scale (GOS).
Categorical variables were described using frequency
and percentage. WFNS grades were dichotomized into
non-severe (WFNS 1–3) and severe (WFNS 4–5), GOS
scales into unfavorable (GOS 1–3) and favorable (GOS
4–5). Continuous variables were described as median and
quartiles if not otherwise indicated. As IL-6 and CRP levels
showed a high variance, the values were logarithmically
transformed for statistical analysis. A variable ‘‘cumulative
NSAID days’’ was defined for semi-quantification and
represents the sum of days (until day 14 after SAH) where
the patients received NSAID, multiplied by the number of
different NSAIDs including acetaminophen. This method-
ological simplification was performed as quantitative
equivalent conversion is not possible for NSAIDs. Occur-
rence of fever was quantified as febrile days, defined as
exceeding threshold core body temperature C38 C for
>1 h at least once per day.
Pearson’s correlation coefficient between median values
of inflammatory markers and cumulative NSAID days was
Table 1 Criteria for infectious complications
Pneumonia Specific signs of alveolar infiltrate on chest X-ray
and microorganism isolated from
tracheobronchial secretion culturesa
Blood stream
infection
Predominant microorganism identified in blood
culturesa
Urinary tract
infection
Isolation of >105 microorganisms/ml in urinary
culturesa
Catheter-related
infection
Isolation of >105 colony-forming units from
catheter tipsa
CSF infection Pleocytosis with positive microbiological cultures
CSF cerebrospinal fluid
a cultures were only obtained in the setting of suspected infection
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calculated. A linear regression analysis was performed to
assess the effect of NSAIDs on inflammatory parameters
unadjusted and adjusted for confounding variables. Appli-
cations of therapeutic hypothermia, WFNS grade,
occurrence of infectious complications, and occurrence of
fever were considered as possible confounding factors. The
correlation between NSAID days and binominal variables
was calculated by a point-biserial correlation analysis. To
investigate whether the application of NSAIDs had an
impact on outcome, an unconditional logistic regression,
unadjusted and adjusted for confounding covariates, was
performed. Age, WFNS grade, occurrence of cerebral
infarctions, and fever were defined as confounding factors,
representing generally accepted, clinically meaningful
predictors in patients with SAH [17–20]. For the significant
factors, odds ratios (OR) and their 95 % confidence inter-
vals (CI) were calculated. A p value <0.05 was regarded
as statistically significant. IBM SPSS Statistics 20.0 Soft-
ware was used.
Results
Of the 209 patients with SAH admitted to the Neurocritical
Care Unit, University Hospital of Zurich, during the 3-year
period, 138 patients were analyzed in the present study.
Exclusion criteria were met in 71 patients. The patients’
characteristics are shown in Table 2. Fifty patients (36 %)
received 2, 38 patients (28 %) received 3, and 12 patients
(9 %) received 4 different types of NSAIDs. Eleven
patients (8 %) received 1 single type of NSAID. The most
frequent NSAID was acetaminophen followed by dipyrone,
diclofenac, and ibuprofen. Overall median cumulative
NSAID days were 15.5 (range 0–42), 20 (range 0–42) in
patients without and 2 (range 0–19) in patients with ther-
apeutic hypothermia. The difference was statistically
highly significant (p < 0.001, Mann–Whitney test). In the
majority of these cases, application of NSAIDs decreased
dramatically as soon as the target temperature was
achieved and maintained. Quantitatively, an inverse cor-
relation could be found between cumulative NSAID days
and number of days with hypothermia (r = -0.677,
p < 0.001). The analysis of the correlation between
cumulative NSAID days and IL-6 established an inverse
correlation (r = -0.437, p < 0.001) (Fig. 1a). Further-
more, there was also a weaker inverse correlation between
the cumulative NSAID days and CRP (r = -0.369,
p < 0.001) (Fig. 1b). A subgroup analysis showed a cor-
relation in patients without hypothermia (r = -0.504,
p < 0.001 for IL-6 and r = -0.326, p < 0.001 for CRP),
while no correlations could be found in patients with
hypothermia. Due to the weaker anti-inflammatory prop-
erties of acetaminophen, a subanalysis was performed
without acetaminophen: The correlation between cumula-
tive NSAID days (without acetaminophen) and IL-6 and
CRP was r = -0.409, p < 0.001 and r = -0.327,
p < 0.001, respectively. The correlations were weaker
than with acetaminophen. A weak positive correlation
between IL-6 and number of febrile days was found
(r = 0.198, p = 0.02), while a correlation between CRP
and number of febrile days could not be found (r = 0.134,
p = 0.12). The partial correlation coefficient between
cumulative NSAID days and IL-6/CRP, adjusted for febrile
days, was stronger than the previous unadjusted coeffi-
cients (r = -0.484, p < 0.001 for IL-6 and r = -0.400,
p < 0.001 for CRP). Analyzing the correlation between
occurrence of cerebral infarction and cumulative NSAID
days, a weak inverse correlation was found (r = -0.222,
p < 0.010). A moderate inverse correlation was found
between cumulative NSAID days and dichotomized out-
come (r = -0.365, p < 0.001). This correlation remained
present after exclusion of patients receiving therapeutic
hypothermia (r = -0.244, p = 0.013). We also found an
inverse correlation between WFNS grade and cumulative
NSAID days (r = -0.409, p < 0.001). As shown in
Table 3, linear regression analysis showed cumulative
NSAID days to be predictive for systemic IL-6 and CRP
levels in an inverse manner, unadjusted and adjusted for
confounding factors. In the logistic regression analysis, the
variable cumulative NSAID days were revealed to be an
inverse predictor for poor outcome (GOS 1–3): OR 0.918
(95 % CI 0.880–0.956, p < 0.001). After exclusion of
patients receiving therapeutic hypothermia, the variable
cumulative NSAID remained an inverse predictor for poor
outcome: OR 0.932 (95 % CI 0.881–0.897, p = 0.016).
After adjustment for confounding factors (WFNS grade,
occurrence of cerebral infarction, age, and febrile days),
cumulative NSAID days remained an independent inverse
predictor for poor outcome: OR 0.921 (95 % CI 0.870–
0.975, p = 0.005). The inclusion of aneurysm treatment
modality in the regression analyses did not alter the result.
The adjusted OR is shown in Table 4. Logistic regression
analysis showed the variable cumulative NSAID days to be
an inverse predictor for the occurrence of cerebral infarc-
tion as well: OR 0.933 (95 % CI 0.884–0.986, p = 0.013).
Discussion
The present study established an inverse relationship
between the amount of NSAIDs applied and systemic
inflammatory parameters (IL-6 and CRP) in the acute
phase (Bday 14) after SAH. Linear regression analysis
showed that the amount of NSAIDs applied was predictive
for lower IL-6 and CRP levels after adjustment for
potentially confounding factors. These results are of
242 Neurocrit Care (2014) 20:240–246
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interest, as high CRP and IL-6 levels in particular have
been associated with worse neurological outcomes in
patients with SAH [3, 5, 21]. In the logistic regression
analysis, the cumulative amount of NSAIDs reduced the
odds for worse functional outcome. Although the occur-
rence of fever was correlated to some extent, the effect of
NSAIDs on inflammatory markers as well as neurological
outcome could not be attributed to the effect of fever alone
in our statistical model. While age, severity of SAH, and
occurrence of cerebral infarction are well-accepted risk
factors for worse outcome [18, 19], the relation between
NSAID application and outcome is a rather new aspect.
This positive impact on the outcome might be partially
related to the decrease in the occurrence of cerebral
infarctions. However, based on the multivariable regression
analysis, NSAID acts beneficially independent from its
ability to avoid the occurrence of cerebral infarctions.
An additional observation of interest is the influence
of the application of therapeutic hypothermia on the
prescription of NSAIDs. The prescription of NSAIDs
decreased dramatically as soon as therapeutic hypothermia
was induced. Although induction and maintenance of
hypothermia were strictly based on a protocol [14], we
were not consciously aware of the fact that the application
of hypothermia led to a decreased prescription of NSA-
IDs, as this aspect was not considered in the protocol up
to date.
Classical NSAIDs applied in the current patient popu-
lation are diclofenac and ibuprofen, both unselective COX
inhibitors. They mainly exert their anti-inflammatory and
analgesic properties by inhibiting the cyclooxygenase
(COX)-2 pathway. COX-2 enzymes synthesize proinflam-
matory prostaglandins (PG). However, they also have an
inhibitory effect on COX-1, which is constitutively
expressed in platelets and is responsible for the formation
of proaggregatory thromboxane A2. Acetaminophen is
often claimed to possess no or only weak anti-inflamma-
tory properties. Therefore, it is generally not considered as
Fig. 1 Inverse correlations of cumulative NSAID days and log IL-6
A) and CRP B) shown as scatterplots. a Pearson’s correlation r =
-0.437 (p < 0.001) and b r = -0.369 (p < 0.001)
Table 2 Patients’ characteristics
Total (n = 138)
Age, y, mean ± SD 55.3 ± 12.9
Sex
Female, n (%) 91 (66 %)
Male, n (%) 47 (34 %)
WFNS Grade
1–3, n (%) 91 (66 %)
4–5, n (%) 47 (34 %)
Aneurysm treatment
Clipping 78 (56 %)
Coiling 60 (44 %)
Temp. C38 C, days, median (range) 2.54 (0–10)
Therapeutic hypothermia
No hypothermia, n (%) 103 (75 %)
Hypothermia, n (%) 35(25 %)
Infectious complications
No infection 63 (46 %)
Infection 75 (54 %)
Cerebral infarction
Cerebral infarction 19 (14 %)
No cerebral infarction 115 (85 %)
Outcome (GOS)
Favorable (GOS 4–5), n (%) 94 (68 %)
Unfavorable (GOS 1–3), n (%) 44 (32 %)
Inflammatory Parameter
IL-6, ng/l, median (Q1; Q3) 7.7 (4.2; 13.8)
CRP, mg/l, median (Q1; Q3) 23 (12; 40)
SD standard deviation, Temp. core body temperature, Q1 under
quartile, Q3 upper quartile
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a NSAID. However, it is noteworthy that this statement is
based largely on early works showing that acetaminophen
does not suppress inflammation associated with rheumatoid
arthritis, whereas anti-inflammatory action has been sup-
ported in different types of inflammatory conditions and
the mechanism of action has been suggested to be its highly
selective COX-2 inhibition [22]. A more contemporary
study suggests a reinvestigation of acetaminophen in terms
of anti-inflammatory mechanisms [22]. Furthermore, the
drug has always been associated with a suppression of PG
synthesis in the CNS [22]. Based on our results, it might be
assumed that acetaminophen has some effect on the
inflammatory response, as the correlations of cumulative
NSAID days with IL-6 and CRP were weaker without
acetaminophen. Another NSAID drug that was included in
the analysis was dipyrone, which has pronounced analgesic
and antipyretic effects, but weak anti-inflammatory effects
as well [23]. Although its mechanism of action is not
entirely clear, it elicits substantial inhibition of COX in
humans. With respect to the COX inhibition, NSAIDs are
reported to act via other mechanisms such as inhibition of
leukocyte–endothelial cell interaction or modulation of
cytokine expressions, including IL-6 [24, 25].
Due to the potential inhibitory effect on platelet aggre-
gation, some neurosurgeons and neurointensivists might be
reluctant to apply NSAIDs for analgesic and antipyretic
purposes after SAH [26–28]. However, there is no evidence
that administration of NSAIDs carries a higher risk for
rebleeding and consecutive worse outcome. In the current
study, no intracranial rebleedings attributable to excessive
NSAIDs’ application could be identified. On the one hand,
there are virtually no consensus and guidelines with regard
to pain management and application of NSAIDs [26–28].
On the other hand, according to the international multi-
disciplinary consensus conference on the critical care
management of SAH, the application of NSAIDs is con-
sidered to be the first-line intervention in order to control
hyperthermia [20]. There is certainly a strong rationale to
avoid fever, as it has been repeatedly connected to worse
outcome [20]. As central thermoregulation might be ham-
pered after SAH, NSAIDs might not be effective enough
though. Advanced temperature controlling using cooling
devices—cooling blankets or an intravascular heat
exchange catheter—might be more effective in these cases.
More recently, Broessner et al. [29] compared the effec-
tiveness of endovascular cooling to maintain normothermia
with standardized, stepwise, escalating fever management
in patients with ischemic or hemorrhagic stroke: Long-
term, catheter-based, prophylactic normothermia signifi-
cantly reduced fever burden. Interestingly, CRP and IL-6
levels were significantly higher, while the application of
NSAIDs was significantly lower in the device group
compared to the controls. A subgroup analysis revealed
that application of NSAIDs led to a significant decrease of
CRP in patients with endovascular cooling. The authors
argued that the combination of advanced temperature
controlling with NSAIDs might have additional neuropro-
tective effects [30]. This has yet to be proven.
There is increasing evidence that the degree of inflam-
matory response is associated with occurrence of secondary
ischemic events and/or worse outcome after SAH [2, 3, 5].
Therefore, there is a strong rationale to suppress inflam-
matory response. In animal experimental studies, NSAIDs
Table 3 Linear regression analysis
B 95 % CI Sig. B 95 % CI Sig.
Upper Lower Upper Lower
Dependent variable: Log IL-6 Dependent variable: Log CRP
Cumulative NSAID days -0.016* -0.022 -0.011 p < 0.001 -0.015* -0.022 -0.009 p < 0.001
-0.019 -0.026 -0.012 p < 0.001 -0.014 -0.023 -0.005 p = 0.002
CI confidence interval, Sig. significance
* unadjusted coefficient
 adjusted for application of therapeutic hypothermia, WFNS grade, occurrence of infectious complications, and fever
Table 4 Logistic regression analysis for unfavorable outcome
OR 95 % CI Sig.
Upper Lower
Cumulative NSAID days 0.924 0.873 0.979 p = 0.007
Age (years) 1.055 1.014 1.098 p = 0.008
Febrile days 1.007 0.85 1.194 p = 0.935
WFNS 1–3 Reference category
WFNS 4–5 0.321 0.122 0.846 p = 0.022
No cerebral
infarction
Reference category
Cerebral infarction 0.348 0.112 1.077 p = 0.067
Coiling Reference category
Clipping 0.582 0.241 1.403 p = 0.228
OR (adjusted) odds ratio, CI confidence interval, Sig. significance
244 Neurocrit Care (2014) 20:240–246
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have been shown to prevent CVS or brain edema after
SAH, either by COX inhibition or other mechanisms such
as inhibition of leukocyte–endothelial cell interactions
[6–8, 10, 31, 32], while dipyrone has been found to be
remarkably neuroprotective in experimental cerebral
ischemia [33].
In theory, the potential inhibitory effect of NSAIDs on
platelet aggregation might act beneficial too as activation
of the coagulation cascade and occurrence of micro-
thrombosis have been discussed to contribute to the
pathogenesis of cerebral infarction [34]. Clinical studies
with antiplatelet therapies showed a trend toward improved
outcome. However, no definite conclusions could be
drawn. On the basis of the current evidence, routine
treatment with antiplatelet agents in order to prevent
cerebral infarction or poor outcome is currently not rec-
ommended [35]. There are virtually no clinical trials
specifically aimed at investigating the role of NSAID on
inflammatory response in patients with SAH. To the best to
our knowledge, only acetylic acid (ASA)—an NSAID with
irreversible COX inhibition—has been clinically evaluated
in a controlled randomized trial. However, the trial was
conducted with the anti-aggregatory effect of ASA in mind,
and not with regard to its anti-inflammatory effect. The
trial did not confirm a beneficial effect of rectal ASA
administration on the occurrence of delayed ischemic
neurological deficit. However, the functional outcome in
patients who received ASA tended to be better [36].
Hypothermia might exert its neuroprotective properties
by attenuation of destructive inflammatory reactions. Mild
hypothermia has been shown to reduce proinflammatory
cytokine levels such as IL-6 after different types of brain
insults, including SAH [16, 37, 38]. As patients with
therapeutic hypothermia need deep analgosedation, there
might be no objective to administer NSAIDs for fever and
pain management. However, the combination of NSAIDs
and mild hypothermia might have synergistic anti-inflam-
matory and neuroprotective effects. This calls for further
examinations, as the answer to the latter question is beyond
the possibilities of the present study due to its limited
sample size and observational nature.
A clear shortcoming of the current study is the fact that
different types of NSAIDs were lumped together for ana-
lysis, despite their different anti-inflammatory potencies.
However, this methodological simplification was per-
formed as quantitative equivalent conversion is not
possible, in contrast to corticosteroids. A separated sub-
analysis for each medication was regarded as questionable
as all medications were applied in a stepwise management
scheme. Further, the drugs mentioned were used not only
as antipyretics but also for pain treatment, and the detailed
discrimination between the two indications could not be
performed due to methodological reasons. Patients with a
better level of consciousness would be expected to both
need more painkillers and have better outcomes than
patients in coma. The inverse correlation between WFNS
grade and cumulative amount of NSAIDs we found sup-
ports this assumption. However, based on the results of the
regression analysis, the amount of NSAIDs remained an
independent predictor for poor outcome. It also has to be
mentioned that the predetermined exclusion criteria might
have biased the current results [5]. Another shortcoming is
the fact that only systemic inflammatory markers were
measured. It would be of great interest to additionally
measure intrathecal inflammatory markers to assess the
impact of NSAIDs, with or without hypothermia, on the
compartmental inflammatory response within the CNS.
Finally, the actual mechanism by which NSAIDs influ-
enced both inflammatory parameters and outcome cannot
be answered.
Conclusions
The results of the current study indicate an inverse corre-
lation between the amounts of NSAIDs applied and
systemic IL-6 and CRP levels in patients with SAH. A
higher amount of NSAID application reduced the odds for
unfavorable outcome. In the present study, therapeutic
hypothermia led to a significant decrease of NSAID
application. In the case of using cooling devices to induce
normo- or hypothermia, the question arises whether to
continue with NSAID application or not, as it might act in a
synergistic manner in terms of ameliorating inflammation.
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